HOWLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Werewolf Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.04+0.06 (+6.12%)
Close on Oct 19, 2026
- Market cap
- $50.54M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
22.4%
11M of 49M shares
Institutional holders
45
9 new, 12 sold out
Net institutional buying
-3M
In Q2 2026
Insider trades, 12 months
0 buys · 163 sales
Net sold $8.67M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | 5,138,703 | 10.60% | 13D (active) amendment | Jun 11, 2026 |
| Peter Kolchinsky | 3,654,307 | 7.50% | 13D (active) amendment | Jun 17, 2026 |
| Adage Capital Management, L.P. | 3,034,255 | 8.38% | 13G (passive) | Dec 11, 2023 |
| PFM Health Sciences, LP | 2,905,465 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
| Moll Peter | 2,537,138 | 5.20% | 13G (passive) | Sep 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HOWL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 2,387,744 | 4.91% | $859.35K | −4,293,563 | 0.01% |
| Balyasny Asset Management L.P. | 1,790,089 | 3.68% | $644.25K | New | 0.00% |
| Vanguard Capital Management LLC | 1,217,976 | 2.51% | $438.47K | – | 0.00% |
| Renaissance Technologies LLC | 674,632 | 1.39% | $242.80K | +158,414 | 0.00% |
| Lynx1 Capital Management LP | 657,786 | 1.35% | $236.74K | – | 0.03% |
| Sphera Funds Management Ltd. | 626,810 | 1.29% | $225.59K | – | 0.03% |
| DC Funds, LP | 589,102 | 1.21% | $212.02K | – | 16.92% |
| Verdad Advisers, LP | 348,709 | 0.72% | $125.50K | +318,949 | 0.12% |
| Geode Capital Management, LLC | 335,815 | 0.69% | $120.90K | −53,672 | 0.00% |
| Bank Of America Corp /De/ | 311,502 | 0.64% | $111.83K | +46,919 | 0.00% |
| XTX Topco Ltd | 271,478 | 0.56% | $97.71K | +220,549 | 0.00% |
| Jane Street Group, LLC | 251,837 | 0.52% | $90.64K | +169,001 | 0.00% |
| UBS Group AG | 215,838 | 0.44% | $77.70K | +148,981 | 0.00% |
| Vanguard Fiduciary Trust Co | 157,726 | 0.32% | $56.78K | – | 0.00% |
| State Street Corp | 119,168 | 0.25% | $42.89K | – | 0.00% |
| Squarepoint Ops LLC | 103,242 | 0.21% | $37.16K | New | 0.00% |
| BlackRock, Inc. | 101,573 | 0.21% | $36.56K | −35 | 0.00% |
| Rangeley Capital, LLC | 100,000 | 0.21% | $35.99K | New | 0.03% |
| Northern Trust Corp | 86,851 | 0.18% | $31.26K | – | 0.00% |
| Alyeska Investment Group, L.P. | 86,554 | 0.18% | $31.15K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 11M | 22.4% | 9 / 9 | 9 / 12 | 3M | 6M |
| Q1 2026 | 48 | 14M | 28.8% | 10 / 9 | 12 / 12 | 2M | 1M |
| Q4 2025 | 51 | 15M | 30.3% | 7 / 13 | 18 / 15 | 1M | 3M |
| Q3 2025 | 62 | 21M | 43.4% | 8 / 10 | 21 / 10 | 1M | 2M |
| Q2 2025 | 65 | 22M | 45.9% | 17 / 15 | 19 / 22 | 2M | 7M |
| Q1 2025 | 70 | 27M | 56.5% | 7 / 24 | 19 / 9 | 1M | 1M |
| Q4 2024 | 73 | 28M | 58.0% | 12 / 29 | 14 / 8 | 1M | 5M |
| Q3 2024 | 69 | 32M | 66.3% | 13 / 26 | 13 / 14 | 3M | 2M |
| Q2 2024 | 71 | 32M | 66.8% | 22 / 23 | 15 / 12 | 5M | 5M |
| Q1 2024 | 61 | 32M | 66.6% | 25 / 15 | 12 / 4 | 6M | 1M |
| Q4 2023 | 41 | 28M | 56.9% | 10 / 13 | 7 / 4 | 4M | 1M |
| Q3 2023 | 35 | 24M | 49.1% | 2 / 11 | 4 / 3 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of HOWL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 873,745 | 1.80% | $314.46K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 344,231 | 0.71% | $123.89K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 214,645 | 0.44% | $96.59K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 54,577 | 0.11% | $24.56K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 42,628 | 0.09% | $19.18K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 23,347 | 0.05% | $10.51K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 500 | 0.00% | $180 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel J. Hicklin | See Remarks, Director | 647,047 | 1.33% | Jan 6, 2025 |
| Michael J. Urban | VP of Finance & Corp. Contr. | 5,284 | 0.01% | Mar 13, 2026 |
| Steven H. Bloom | Chief Business Officer | – | – | May 2, 2025 |
| Randi Isaacs | Chief Medical Officer | – | – | Jan 6, 2025 |
| Timothy W. Trost | Chief Financial Officer | – | – | Jan 6, 2025 |
| Chulani Karunatilake | Chief Technology Officer | – | – | Jan 6, 2025 |
| Ellen Lubman | Chief Business Officer | – | – | Jan 6, 2025 |
| Luke Evnin | Director | 0 | – | Jul 8, 2026 |
| Meeta Chatterjee | Director | – | – | Jun 13, 2025 |
| Briggs Morrison | Director | 15,523 | 0.03% | Jun 13, 2025 |
| Alon Lazarus | Director | 1,235,917 | 2.54% | Jun 13, 2025 |
| Michael A. Sherman | Director | – | – | Jun 13, 2025 |
| Anil K. Singhal | Director | – | – | Jun 13, 2025 |
| Michael B. Atkins | Director | 14,419 | 0.03% | Jun 13, 2025 |
| RA Capital Nexus Fund II, L.P. | Director, 10% owner | 6,237,482 | 12.83% | May 14, 2025 |
| Rajeev M. Shah | 10% owner | 5,701,056 | 11.73% | Jun 22, 2026 |
| Peter Kolchinsky | 10% owner | 5,076,685 | 10.45% | Jun 22, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 4,291,881 | 8.83% | Jun 22, 2026 |
| Ra Capital Management, L.P. | 10% owner | 303,719 | 0.62% | Jun 22, 2026 |
| BioVentures 2014 GP LLC MPM | – | 5,125,770 | 10.55% | Dec 4, 2025 |
| Oncology Innovations Fund GP LLC MPM | – | 5,125,770 | 10.55% | Dec 4, 2025 |
| Ansbert Gadicke | – | – | – | Dec 4, 2025 |
| MPM BioVentures 2014 (B), L.P. | – | 4,784,111 | 9.84% | Dec 4, 2025 |
| BioVentures 2014 LLC MPM | – | 5,321,436 | 10.95% | Dec 4, 2025 |
| Asset Management Investors BV2014 LLC MPM | – | 4,983,843 | 10.26% | Dec 4, 2025 |
| MPM BioVentures 2014, L.P. | – | 5,691,191 | 11.71% | Dec 4, 2025 |
| Oncology Innovations Fund Lp Mpm | – | 6,147,610 | 12.65% | Dec 4, 2025 |
| Asset Management Llc Mpm | – | 6,723,056 | 13.83% | Dec 4, 2025 |
| BioImpact LLC MPM | – | 4,784,111 | 9.84% | Dec 4, 2025 |
| Impact Fund (Cayman) Management L.P. Oncology | – | – | – | Dec 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Luke Evnin Director | Jul 7, 2026 | Sale(10b5-1 plan) | −107,429 | $0.31 | $33.30K | 0 |
| Luke Evnin Director | Jul 6, 2026 | Sale(10b5-1 plan) | −35,770 | $0.32 | $11.45K | 107,429 |
| Luke Evnin Director | Jun 29, 2026 | Sale(10b5-1 plan) | −157,084 | $0.30 | $47.13K | 143,199 |
| Ra Capital Management, L.P. 10% owner | Jun 17, 2026 | Sale | −27,695 | $0.35 | $9.69K | 303,719 |
| Ra Capital Management, L.P. 10% owner | Jun 17, 2026 | Sale | −389,216 | $0.35 | $136.23K | 4,268,448 |
| Ra Capital Management, L.P. 10% owner | Jun 16, 2026 | Sale | −9,939 | $0.37 | $3.68K | 331,414 |
| Ra Capital Management, L.P. 10% owner | Jun 16, 2026 | Sale | −139,686 | $0.37 | $51.68K | 4,657,664 |
| Ra Capital Management, L.P. 10% owner | Jun 15, 2026 | Sale | −8,554 | $0.39 | $3.34K | 341,353 |
| Ra Capital Management, L.P. 10% owner | Jun 15, 2026 | Sale | −120,216 | $0.39 | $46.88K | 4,797,350 |
| Ra Capital Management, L.P. 10% owner | Jun 12, 2026 | Sale | −11,322 | $0.40 | $4.53K | 349,907 |
| Ra Capital Management, L.P. 10% owner | Jun 12, 2026 | Sale | −159,119 | $0.40 | $63.65K | 4,917,566 |
| Peter Kolchinsky 10% owner | Jun 11, 2026 | Sale | −245,066 | $0.38 | $93.13K | 5,076,685 |
| Peter Kolchinsky 10% owner | Jun 11, 2026 | Sale | −17,437 | $0.38 | $6.63K | 361,229 |
| Peter Kolchinsky 10% owner | Jun 10, 2026 | Sale | −3,051 | $0.37 | $1.13K | 378,666 |
| Peter Kolchinsky 10% owner | Jun 10, 2026 | Sale | −42,872 | $0.37 | $15.86K | 5,321,751 |
| Peter Kolchinsky 10% owner | Jun 9, 2026 | Sale | −24,565 | $0.37 | $9.09K | 381,717 |
| Peter Kolchinsky 10% owner | Jun 9, 2026 | Sale | −345,235 | $0.37 | $127.74K | 5,364,623 |
| Luke Evnin Director | Jun 9, 2026 | Sale(10b5-1 plan) | −76,928 | $0.37 | $28.46K | 300,283 |
| Luke Evnin Director | Jun 8, 2026 | Sale(10b5-1 plan) | −60,547 | $0.40 | $24.22K | 377,211 |
| Luke Evnin Director | Jun 5, 2026 | Sale(10b5-1 plan) | −24,946 | $0.40 | $9.98K | 437,758 |
| Luke Evnin Director | Jun 4, 2026 | Sale(10b5-1 plan) | −20,072 | $0.44 | $8.83K | 462,704 |
| Luke Evnin Director | Jun 3, 2026 | Sale(10b5-1 plan) | −29,749 | $0.42 | $12.49K | 482,776 |
| Luke Evnin Director | Jun 2, 2026 | Sale(10b5-1 plan) | −29,595 | $0.45 | $13.32K | 512,525 |
| Luke Evnin Director | Jun 1, 2026 | Sale(10b5-1 plan) | −80,459 | $0.47 | $37.82K | 542,120 |
| Luke Evnin Director | May 29, 2026 | Sale(10b5-1 plan) | −32,556 | $0.45 | $14.65K | 622,579 |
| Luke Evnin Director | May 28, 2026 | Sale(10b5-1 plan) | −27,698 | $0.46 | $12.74K | 655,135 |
| Luke Evnin Director | May 27, 2026 | Sale(10b5-1 plan) | −80,852 | $0.48 | $38.81K | 682,833 |
| Luke Evnin Director | May 26, 2026 | Sale(10b5-1 plan) | −67,950 | $0.47 | $31.94K | 763,685 |
| Luke Evnin Director | May 22, 2026 | Sale(10b5-1 plan) | −87,425 | $0.45 | $39.34K | 831,635 |
| Luke Evnin Director | May 21, 2026 | Sale(10b5-1 plan) | −36,387 | $0.42 | $15.28K | 919,060 |
| Luke Evnin Director | May 20, 2026 | Sale(10b5-1 plan) | −85,895 | $0.43 | $36.93K | 955,447 |
| Luke Evnin Director | May 19, 2026 | Sale(10b5-1 plan) | −62,970 | $0.45 | $28.34K | 1,041,342 |
| Luke Evnin Director | May 18, 2026 | Sale(10b5-1 plan) | −22,184 | $0.50 | $11.09K | 1,104,312 |
| Luke Evnin Director | May 13, 2026 | Sale(10b5-1 plan) | −44,679 | $0.54 | $24.13K | 1,126,496 |
| Ra Capital Management, L.P. 10% owner | May 12, 2026 | Sale | −94,432 | $0.64 | $60.44K | 5,709,858 |
| Ra Capital Management, L.P. 10% owner | May 12, 2026 | Sale | −6,719 | $0.64 | $4.30K | 406,282 |
| Luke Evnin Director | May 12, 2026 | Sale(10b5-1 plan) | −67,885 | $0.64 | $43.45K | 1,171,175 |
| Ra Capital Management, L.P. 10% owner | May 11, 2026 | Sale | −81,678 | $0.67 | $54.72K | 5,804,290 |
| Ra Capital Management, L.P. 10% owner | May 11, 2026 | Sale | −5,812 | $0.67 | $3.89K | 413,001 |
| Luke Evnin Director | May 11, 2026 | Sale(10b5-1 plan) | −33,948 | $0.67 | $22.75K | 1,239,060 |
| Ra Capital Management, L.P. 10% owner | May 8, 2026 | Sale | −25,012 | $0.71 | $17.76K | 418,813 |
| Ra Capital Management, L.P. 10% owner | May 8, 2026 | Sale | −351,514 | $0.71 | $249.57K | 5,885,968 |
| Luke Evnin Director | May 8, 2026 | Sale(10b5-1 plan) | −305,741 | $0.70 | $214.02K | 1,273,008 |
| Luke Evnin Director | May 7, 2026 | Sale(10b5-1 plan) | −79,086 | $0.63 | $49.82K | 1,578,749 |
| Luke Evnin Director | May 6, 2026 | Sale(10b5-1 plan) | −14,635 | $0.66 | $9.66K | 1,657,835 |
| Luke Evnin Director | May 5, 2026 | Sale(10b5-1 plan) | −6,860 | $0.69 | $4.73K | 1,672,470 |
| Luke Evnin Director | May 4, 2026 | Sale(10b5-1 plan) | −47,963 | $0.72 | $34.53K | 1,679,330 |
| Luke Evnin Director | May 1, 2026 | Sale(10b5-1 plan) | −58,394 | $0.73 | $42.63K | 1,727,293 |
| Luke Evnin Director | Apr 30, 2026 | Sale(10b5-1 plan) | −168,262 | $0.72 | $121.15K | 1,785,687 |
| Luke Evnin Director | Apr 29, 2026 | Sale(10b5-1 plan) | −56,559 | $0.69 | $39.03K | 1,953,949 |
| Luke Evnin Director | Apr 28, 2026 | Sale(10b5-1 plan) | −95,412 | $0.73 | $69.65K | 2,010,508 |
| Luke Evnin Director | Apr 27, 2026 | Sale(10b5-1 plan) | −53,940 | $0.85 | $45.85K | 2,105,920 |
| Luke Evnin Director | Jan 16, 2026 | Sale(10b5-1 plan) | −38,782 | $0.54 | $20.94K | 2,159,860 |
| Luke Evnin Director | Jan 15, 2026 | Sale(10b5-1 plan) | −37,413 | $0.55 | $20.58K | 2,198,642 |
| Luke Evnin Director | Jan 14, 2026 | Sale(10b5-1 plan) | −30,616 | $0.57 | $17.45K | 2,236,055 |
| Luke Evnin Director | Jan 13, 2026 | Sale(10b5-1 plan) | −43,198 | $0.55 | $23.76K | 2,266,671 |
| Luke Evnin Director | Jan 12, 2026 | Sale(10b5-1 plan) | −58,980 | $0.57 | $33.62K | 2,309,869 |
| Luke Evnin Director | Jan 9, 2026 | Sale(10b5-1 plan) | −24,678 | $0.61 | $15.05K | 2,368,849 |
| Luke Evnin Director | Jan 8, 2026 | Sale(10b5-1 plan) | −7,716 | $0.63 | $4.86K | 2,393,527 |
| Luke Evnin Director | Jan 7, 2026 | Sale(10b5-1 plan) | −11,915 | $0.64 | $7.63K | 2,401,243 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| UBS Oncology Impact Fund, L.P. Shareholder | Jul 6, 2026 | 80,142 | $27.28K | Jul 6, 2026 | Private Placement |
| Asset Management LLC MPM Shareholder | Jul 6, 2026 | 15,341 | $5.22K | Jul 6, 2026 | Private Placement |
| Asset Management Investors BV2014 LLC MPM Shareholder | Jul 6, 2026 | 3,332 | $1.13K | Jul 6, 2026 | Private Placement |
| MPM BioVentures 2014, L.P. Shareholder | Jul 6, 2026 | 96,873 | $32.98K | Jul 6, 2026 | Private Placement |
| MPM BioVentures 2014 (B), L.P. Shareholder | Jul 6, 2026 | 6,459 | $2.20K | Jul 6, 2026 | Private Placement |
| MPM Oncology Innovations Fund, L.P. Shareholder | Jul 6, 2026 | 21,194 | $7.21K | Jul 6, 2026 | Private Placement |
| MPM BioVentures 2014, L.P. Shareholder | Jun 29, 2026 | 106,262 | $34.32K | Jun 29, 2026 | Private Placement |
| MPM BioVentures 2014 (B), L.P. Shareholder | Jun 29, 2026 | 7,087 | $2.29K | Jun 29, 2026 | Private Placement |
| UBS Oncology Impact Fund, L.P. Shareholder | Jun 29, 2026 | 87,916 | $28.40K | Jun 29, 2026 | Private Placement |
| Asset Management LLC MPM Shareholder | Jun 29, 2026 | 16,830 | $5.44K | Jun 29, 2026 | Private Placement |
| Asset Management Investors BV2014 LLC MPM Shareholder | Jun 29, 2026 | 3,657 | $1.18K | Jun 29, 2026 | Private Placement |
| MPM Oncology Innovations Fund, L.P. Shareholder | Jun 29, 2026 | 23,248 | $7.51K | Jun 29, 2026 | Private Placement |
| MPM Oncology Innovations Fund, L.P. Shareholder | May 28, 2026 | 53,425 | $26.18K | May 28, 2026 | Private Placement |
| Asset Management Investors BV2014 LLC MPM Shareholder | May 28, 2026 | 8,405 | $4.12K | May 28, 2026 | Private Placement |
| Asset Management LLC MPM Shareholder | May 28, 2026 | 38,675 | $18.95K | May 28, 2026 | Private Placement |